Ipilimumab — Drug Intelligence | 88 EU Trials

Filter these 88 trials by condition, phase, country and more.

Open in Search →

88 Registered trials

30 Recruiting

46 Completed trials

50 Sponsors

18 Countries

Phase III

Phase II

Phase I/II

Phase III: 23 Phase II/III: 6 Phase II: 36 Phase I/II: 13 Phase IV: 3 Phase I (Other): 4 Phase I (FiH): 3

Oversight events:

3 serious breaches 8 temporary halts 1 urgent safety measure 1 unexpected event across 6 trials

View oversight register →

Indications tested

Non-small cell lung cancer 5 Uveal melanoma 4 Malignant melanoma 3 Malignant melanoma stage IV 2 Malignant melanoma stage III 2 Metastatic renal cell carcinoma 2 Pleural mesothelioma malignant 2 Colorectal cancer 2 Metastatic malignant melanoma 2 Hepatocellular carcinoma 2 Colon cancer stage IV 1 Colorectal cancer stage III 1

Sponsors using this IMP

Bristol Myers Squibb International Corporation 10 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 10 Bristol-Myers Squibb Services Unlimited Company 8 Amsterdam UMC Stichting 3 Institut Gustave Roussy 3 Pfizer Inc. 3 Region Hovedstaden 3 European Organisation For Research And Treatment Of Cancer 2 Exelixis Inc. 2 Ideaya Biosciences Inc. 2 Odense University Hospital 2 UZ Brussel 2

All trials

88 total

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE META… Not authorised

2023-506686-66-00 Phase II/III 1 country Ideaya Biosciences Inc.
Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo… Pending

2023-508658-24-00 Phase II 4 countries European Organisation For Research And Treatment Of Cancer
A study to investigate efficacy of RP2 with nivolumab compared to ipilimumab with nivolumab in adult patients with advanced uveal melanoma n… Pending

2023-508784-68-00 Phase II/III 5 countries Replimune Inc.
CHOPIN Pending

2024-516127-14-01 Phase I (FiH) 1 country Leids Universitair Medisch Centrum (LUMC)
Changes in the tumour microenvironment after intravenous or intradermal administration of anti-CTLA-4 in combination with anti-PD1 treatment… Pending

2024-516545-39-01 Phase I/II 1 country Stichting Amsterdam UMC
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Pending

2024-518138-10-00 Phase II 1 country Association Gercor
Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X Study Pending

2024-518545-13-00 Phase II 1 country Melanoma Institute Australia
Evaluation study of a treatement with Nivolumab and Ipilimumab or tKi according to molecular group in naïve metastatic Kidney cancer Pending

2024-520045-23-00 Phase II 1 country ARTIC
The MAYA2 trial Pending

2025-521941-25-00 Phase II 1 country Odense University Hospital
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally… Pending

2025-523524-53-00 Phase I/II 2 countries Pfizer Inc.
Symbiotic-GI-13, A Study to Learn About the Study Medicine Called PF-08634404 as Monotherapy and Combination Therapy in Adult Participants w… Pending

2025-523525-17-00 Phase I/II 4 countries Pfizer Inc.
Trial to study the safety and pharmacokinetics of ODM-212 combined with existing cancer treatments Pending

2025-524620-22-00 Phase I/II 4 countries Orion Corporation
SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting

2024-517062-42-00 Phase III 3 countries Immatics US Inc.
A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC Recruiting

2025-523602-33-00 Phase I/II 5 countries Bristol-Myers Squibb Services Unlimited Company
IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator… Recruiting

2025-522500-24-00 Phase III 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onc… Recruiting

2025-523620-44-02 Phase IV 1 country Semmelweis University
NEOREM/NEO-1 - NEOREM: Neo-adjuvant Immunotherapy Master Trial for Localized Cancers / NEO-1: Neo-adjuvant immunotherapy in patients with l… Recruiting

2025-522127-95-00 Phase II 1 country Unicancer
NEoadjuvant Chemotherapy and Immunotherapy for a selected group of inoperable pleural Mesothelioma patients (NECIM): a feasibility study Recruiting

2023-504302-11-02 Phase II 1 country Antwerp University Hospital
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE… Recruiting

2024-517789-41-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melano… Recruiting

2024-519593-39-00 Phase III 1 country Karolinska University Hospital
Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing morbid curative sur… Recruiting

2024-516152-17-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran… Recruiting

2023-503326-39-00 Phase III 1 country Institut Gustave Roussy
Phase II study of Roginolisib in UM patients Recruiting

2024-514333-37-00 Phase II 2 countries iOnctura SA
Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study Recruiting

2024-518878-14-01 Phase IV 1 country Isala Klinieken Stichting

Showing 1–24 of 88 trials

← All drugs A–Z